Since mutations or loss of the TP53 gene leads to evasion of senescence and other tumor suppressor functions in the progression of multiple tumor types (55–57), we asked if TP53 loss could overcome the observed necessity for AGO2 in mutant NRAS-driven cancers. This evidence concerns the gene TP53 and neoplasm.